A major breakthrough in the field of prostate cancer research was announced last summer. For the first time in a randomized clinical trial, a drug was found to reduce the risk of prostate cancer. Widely reported headlines such as "Drug might prevent prostate cancer, researchers say" (USA Today, June 25, 2003, page 1) were tempered by reports of the drug's "disturbing" side effects.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.